New York, May 20, 2026, 17:07 (EDT)
Immunovant shares closed 35.3% higher at $35.56 on Wednesday after the biotech company reported encouraging 16-week data for its experimental rheumatoid arthritis drug, IMVT-1402, a move that made the stock one of the day’s standout U.S. healthcare gainers. Roivant Sciences, Immunovant’s majority owner, also rose sharply, closing about 14.9% higher at $32.41.
The rally mattered because investors had been waiting for evidence that IMVT-1402, now Immunovant’s central asset, could work beyond its lead autoimmune programs. The move also outpaced a firmer broader market, with the Nasdaq up 1.55% and the S&P 500 up 1.08% late Wednesday, according to Investing.com market data.
Immunovant said IMVT-1402 produced ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8%, respectively, after 16 weeks in the open-label part of a study in difficult-to-treat rheumatoid arthritis. ACR20 is a standard arthritis measure meaning at least a 20% improvement in tender and swollen joint counts, plus improvement in other clinical measures.
The trial enrolled 170 patients and evaluated a 600-mg weekly subcutaneous dose, meaning an injection under the skin. Of 165 evaluable patients, 86.7% had failed two prior mechanisms of advanced therapy, making the readout more relevant to investors focused on a hard-to-treat population where treatment options are thin.
In the subset of patients who had failed at least a JAK inhibitor and an anti-TNF drug — two major classes used in rheumatoid arthritis — Immunovant reported ACR20, ACR50 and ACR70 response rates of 72.0%, 53.3% and 37.4%. The company said no new drug-related safety signals were seen and that independent assessors, who checked joints without knowing treatment status, were used to limit bias.
Leerink Partners analyst David Risinger called the data “highly compelling” and wrote that the results gave IMVT-1402 the “potential to become a blockbuster,” industry shorthand for a drug with annual sales above $1 billion. The analyst’s view helped frame the readout as more than a one-day clinical update. Investors.com
Roivant CEO Matt Gline said the Period 1 data showed “exciting potential for a new, differentiated mechanism” in rheumatoid arthritis patients who had failed several prior therapies. Roivant said further updates from the rheumatoid arthritis trial, along with top-line data from a cutaneous lupus erythematosus study, are expected in the second half of 2026. Roivant Sciences Ltd.
The drug targets the neonatal Fc receptor, or FcRn, a protein that helps keep IgG antibodies circulating in the body. Blocking FcRn is meant to speed the breakdown of harmful IgG autoantibodies, which can drive autoimmune disease; rivals in the broader FcRn field include argenx’s Vyvgart, UCB’s Rystiggo and Johnson & Johnson’s Imaavy, though those drugs are mainly tied to myasthenia gravis rather than rheumatoid arthritis.
The clinical news overshadowed a weaker financial line. Immunovant reported a fiscal fourth-quarter net loss of $147.9 million, or 73 cents per share, while MarketBeat showed consensus at a 60-cent loss; the company said research and development spending rose as it advanced IMVT-1402 trials and booked costs tied to ending work on batoclimab.
Cash helped the story. Immunovant ended March with about $902.1 million in cash and cash equivalents and said that was enough to fund announced indications through the potential commercial launch of IMVT-1402 in Graves’ disease. The company expects 2027 top-line data from potentially registrational trials in Graves’ disease and myasthenia gravis.
But the risk is still clinical. The rheumatoid arthritis data came from an open-label period, not a fully blinded, placebo-controlled efficacy readout, and the ongoing randomized withdrawal portion could read differently. Roivant also warned that product-candidate potential, trial timing, approvals and commercial outcomes remain forward-looking and subject to risks, including later trials not matching early results.
For now, investors are treating the readout as a reset for Immunovant after April’s Phase 3 miss for batoclimab in thyroid eye disease, which led the company to discontinue batoclimab across all indications and focus on IMVT-1402. The next test is whether the company can turn Wednesday’s strong early signal into a cleaner regulatory path — and keep the stock’s new premium from running ahead of the data.
